Immunohistochemistry or IHC
Brief Report: Multimodality Therapy in Patients with Primary Pericardial Mesothelioma
Journal of Thoracic Oncology 2022 September 5 [Link] Michael Offin, Dilanka De Silva, Jennifer L Sauter, Jacklynn V Egger, Ellen Yorke, Prasad S Adusumilli, Andreas Rimner, Valerie W Rusch, Marjorie G Zauderer Abstract Background: Primary pericardial mesothelioma (PPM) has no accepted standard of care treatment options with management and outcomes often extrapolated from diffuse pleural…
Read MoreHypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases
Histopathology 2022 August 25 [Link] Andrew Churg, Julia R Naso Abstract Separation of mesothelioma from metastatic carcinoma requires immunohistochemical support, with small batteries of stains recommended as a starting-point, but these numbers commonly expand to 10, 12 or more stains, a process that is not only expensive but frequently generates anomalous or confounding results, leading…
Read MoreDiagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma
Journal of the American Society of Cytopathology 2022 July 9 [Link] Louise Andersen Lynggård, Vasiliki Panou, Weronika Szejniuk, Oluf Dimitri Røe, Christos Meristoudis Abstract Introduction: Serous effusion is often the first sign of mesothelioma. Diagnosis based on cytologic material from the effusions remains controversial and complementary biopsy is usually required. However, obtaining representative tissue sample…
Read MoreTumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells
Thoracic Cancer 2022 August 2 [Link] Masayoshi Hasegawa, Yuki Hanamatsu, Chiemi Saigo, Yusuke Kito, Tamotsu Takeuchi Abstract Background: As mesothelioma generally has an unfavorable prognosis, further advances are needed to improve the outcomes in patients with mesothelioma. In the present study, we generated and characterized a monoclonal antibody that could inhibit mesothelioma cell proliferation in…
Read MoreSera from Patients with Malignant Pleural Mesothelioma Tested Positive for IgG Antibodies against SV40 Large T Antigen: The Viral Oncoprotein
Journal of Oncology 2022 July 15 [Link] Elisa Mazzoni, Ilaria Bononi, John Charles Rotondo, Chiara Mazziotta, Roberta Libener, Roberto Guaschino, Roberta Gafà, Giovanni Lanza, Fernanda Martini, Mauro Tognon Abstract Malignant pleural mesothelioma (MPM), a fatal tumor, is mainly linked to the asbestos exposure. It has been reported that together with the inhalation of asbestos fibers,…
Read MoreClinical significance of 9P21 gene combined with BAP1 and MTAP protein expression in diagnosis and prognosis of mesothelioma serous effusion
Biomedical Reports 2022 June 7 [Link] Guan-Ying Ma, Shuai Shi, Ping Wang, Xing-Guang Wang, Zhi-Gang Zhang Abstract The diagnostic value of the 9P21 gene determined using fluorescence in situ hybridization (FISH) combined with BRCA1-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) expression detection by immunohistochemistry, was investigated in serous effusion samples of malignant mesothelioma. A…
Read MorePrognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma
Frontiers in Oncology 2022 June 20 [Link] Hely Ollila, Mikko I Mäyränpää, Lassi Paavolainen, Juuso Paajanen, Katja Välimäki, Eva Sutinen, Henrik Wolff, Jari Räsänen, Olli Kallioniemi, Marjukka Myllärniemi, Ilkka Ilonen, Teijo Pellinen Abstract Background: Pleural mesothelioma (MPM) is an aggressive malignancy with an average patient survival of only 10 months. Interestingly, about 5%-10% of the…
Read MoreChallenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features
Annals of Diagnostic Pathology 2022 June 30 [Link] Prakasit Sa-Ngiamwibool, Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Takahiko Kasai, Kenzo Hiroshima, Kei Kushitani, Yukio Takeshima, Kunimitsu Kawahara, Akinori Iwasaki, Kazuki Nabeshima Abstract Aim: Genomic-based ancillary assays including immunohistochemistry (IHC) for BRCA-1 associated protein-1 (BAP1) and methylthioadenosine phosphorylase (MTAP), and fluorescence in situ…
Read MoreA Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas
Archives of Pathology & Laboratory Medicine 2022 June 23 [Link] Luka Brcic, Nolwenn Le Stang, Florian Gallob, Daniel Pissaloux, Ruth Sequeiros, Sandrine Paindavoine, Jean Claude Pairon, Marie Karanian, Sanja Dacic, Nicolas Girard, Andrew Churg, Franck Tirode, Francoise Galateau-Salle Abstract Context.—: Homozygous deletion (HD) of CDKN2A is one of the most frequent genetic abnormalities in pleural…
Read MoreAdenomatoid mesothelioma arising from the diaphragm: a case report and review of the literature
Journal of Medical Case Reports 2022 May 30 [Link] Kenta Kawabe, Hiroki Sato, Akiko Kitano, Ryuichi Yoshida, Kazuya Yasui, Yuzo Umeda, Kazuhiro Yoshida, Tomokazu Fuji, Kenjiro Kumano, Kosei Takagi, Masaaki Kagoura, Takahito Yagi, Toshiyoshi Fujiwara Abstract Background: Adenomatoid mesothelioma is a rare subtype of malignant mesothelioma that can be confused with adenomatoid tumors, which are…
Read More